Zolbetuximab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Zolbetuximab
Accession Number
DB15118
Type
Biotech
Groups
Investigational
Description

Zolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).

Synonyms
Not Available
External IDs
IMAB362
Categories
UNII
TF5MPQ8WGY
CAS number
1496553-00-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Zolbetuximab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Zolbetuximab.
AbrilumabThe risk or severity of adverse effects can be increased when Abrilumab is combined with Zolbetuximab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Zolbetuximab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Zolbetuximab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Zolbetuximab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Zolbetuximab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zolbetuximab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Zolbetuximab.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Zolbetuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCLDN18.2-positive Adenocarcinoma of Esophagus / CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction / CLDN18.2-positive Gastric Adenocarcinoma1
1Not Yet RecruitingTreatmentGastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma1
1RecruitingTreatmentGastro-esophageal Junction (GEJ) Cancer / Malignant Neoplasm of Stomach1
2CompletedTreatmentCLDN18.2-positive Adenocarcinoma of Esophagus / CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction / CLDN18.2-positive Gastric Adenocarcinoma1
2CompletedTreatmentTumors, Solid1
2RecruitingTreatmentGastro-esophageal Junction (GEJ) Cancer / Malignant Neoplasm of Stomach / Pharmacokinetics of Fluorouracil Bolus (5-FU) / Pharmacokinetics of IMAB362 / Pharmacokinetics of Oxaliplatin / Pharmacokinetics of Zolbetuximab1
2RecruitingTreatmentMalignant Neoplasm of Pancreas / Pancreatic Adenocarcinoma Metastatic / Pancreatic Cancer Metastatic1
3RecruitingTreatmentLocally Advanced Unresectable Gastric Adenocarcinoma or Cancer / Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer / Metastatic Gastric Adenocarcinoma or Cancer / Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:51 / Updated on September 02, 2019 20:27